THE TAPE
STAA · Ophthalmic Goods · $1.3B

Staar Surgical Co

$26.01▼ −1.44%
Last close
Relative strength
36RS
of 99, against every stock▲ +16 on the month
Turning up
Turning
−19.6%
six months against the S&P 500
52-week range
−27.5%
from the high
$15.59$35.87
Setup
multi yearplayed out
−18.7%
against the pivot at $32.00
No report date on the calendar.
Growth WEAKProof SHOWN
Quarter to Oct 2, revenue −12% on a year ago
11/16 O 26.12 H 26.44 L 25.81 Vol 568.1K
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

RS36
vs pivot−18.72%
Tightening1.28×
Dry-up0.93×
Up/down vol-0.12
From high27%
played out3 of 9checks
Turning up
Support and resistance
Support below
$25.87
-0.5% · tested 3× · last 65 sessions ago
Resistance above
$28.10
+8.0% · tested 4× · last 92 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 75.6 weeks and fell 58% from its ceiling at its deepest. The pivot is $32.00, and the stock closed 18.7% below it. Its relative strength rating is 36.

Against its industry
TurningBehind its industry over six months, but ahead over one and three.
One month against the S&P 500
+26.1%
Three months against the S&P 500
+9.5%
Six months against the S&P 500
-19.6%

Its industry has too few members to make an index of, so it is read against the S&P 500 and can only be turning, caution or unconfirmed.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 7.5% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$328.3M
-12.0% year on year
Operating margin
0.2%
gross 73.6%
Net margin
0.2%
Free cash flow
$17.8M
1.4% of market cap
Price to sales
3.97×
Price to earnings
2460.8×

Twelve months to Oct 2, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 4
Key takeaway
Revenue is falling but the business still generates cash.
Revenue
$83.4M
-10.8% QoQ · -12.0% YoY
Gross margin
70.9%
-3.6 pts QoQ
Net income
$5.6M
Positive
Free cash flow
$26.4M
Cash generating

What the numbers say

  • Weak: Revenue -12.0% year over year, -10.8% on the quarter
  • Weak: Gross margin 70.9%, -3.6 points on the quarter
  • Good: Profitable: net income $6M, operating margin 6.5%
  • Good: Cash generating: operating cash flow $27M, free cash flow $26M
  • Good: Net cash $134M · cash $134M
Revenue by quarter
Free cash flow
Net income
shares +1.8% in a year · net cash $133.6M
Final read
Growth: WEAK · Economic proof: SHOWN
Key question: Can the cash generation hold as growth slows?
The next test is revenue growth: revenue -12.0% year over year, -10.8% on the quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

No tracked fund holds it now at the end of Q3 2026.

Last quarter: 1 sold out.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-12
+11.8%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Reported resultsFiling · 2026-11-11
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Unusual volumeTape · 2026-11-11
3.2 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-10
above 20d & 50d on 2.4x volume at 24.55
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
Unusual volumeTape · 2026-11-10
3.4 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
GappedTape · 2026-11-07
-5.7%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-06
above 20d & 50d on 2.1x volume at 26.72
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
GappedTape · 2026-11-05
+7.9%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Merit Medical (MMSI) Q3 Earnings and Revenues Beat EstimatesZacks Investment Research · 2026-10-29

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders

Nobody bought or sold on the open market in the last 6 months. There were 20 filings for awards, option exercises or shares withheld to pay tax — those happen on a vesting schedule, so they are not a decision to buy or sell.

Most recent filings
2026-08-14 Foust Warren · President and CEOoption exercise7,331
2026-08-14 Foust Warren · President and CEOwithheld for tax3,730$97,651
2026-08-14 Foust Warren · President and CEOoption exercise3,666
2026-08-14 Foust Warren · President and CEOwithheld for tax1,865$48,826
2026-08-14 ANDREWS DEBORAH J · Chief Financial Officer & EVPoption exercise5,233
2026-08-14 ANDREWS DEBORAH J · Chief Financial Officer & EVPwithheld for tax2,662$69,691
2026-08-14 Michna Magda · Chief Development Officeroption exercise5,499
2026-08-14 Michna Magda · Chief Development Officerwithheld for tax2,797$73,225

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What lines up

3 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy0
Buy4
Hold6
Sell1
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Staar Surgical Co (STAA) — The Tape